Press releases
- Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
- Flagship Pioneering Unveils Prologue Medicines to Unlock the Therapeutic Potential of the Viral Proteome
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
- Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
More ▼
Key statistics
On Thursday, Seres Therapeutics Inc (1S9:DUS) closed at 0.7906, 60.82% above the 52 week low of 0.4916 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8026 |
---|---|
High | 0.827 |
Low | 0.8024 |
Bid | -- |
Offer | -- |
Previous close | 0.7906 |
Average volume | 1.52k |
---|---|
Shares outstanding | 151.45m |
Free float | 142.82m |
P/E (TTM) | -- |
Market cap | 139.32m USD |
EPS (TTM) | -0.6062 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼